C

Claritas Rx

Biopharma data integration and analytics platform

Controller

Full-TimeUpdated on 10/23/2026
$180k - $220k+ Stock options
Expert
Bachelor's, Master's
South San Francisco, CA, USA
HybridHybrid; 2 days per week in the South San Francisco office.
AccountingFinancial Accounting

About the job

Requirements
  • Must be based in San Francisco and work hybrid, with two days per week in the South San Francisco office.
  • Bachelor’s degree in accounting or finance.
  • Proven experience as a Controller in SaaS or recurring-revenue businesses, with deep technical knowledge of ASC 606/IFRS 15 for SaaS and service contracts.
  • Mastery of NetSuite, Bill, and related accounting and finance systems.
  • Demonstrated experience with complex contracting, invoicing, and revenue recognition, including customers with multiple concurrent statements of work, mixed revenue types, and shifting delivery timeframes, and the ability to understand the complete contract-to-revenue lifecycle.
  • Track record of designing and driving accounting and operational process change, ideally in high-growth, private-equity, or startup environments.
  • Hands-on financial planning and analysis experience, including Budget versus Actual reporting, forecasting, and building or running an operating financial model.
  • Demonstrated ability to lead teams, scale systems, and deliver timely, accurate financial reporting.
  • Strong analytical, organizational, and communication skills.
Responsibilities
  • Direct and control accounting operations, including the general ledger, accounts payable and receivable, payroll, and month-, quarter-, and year-end close activities.
  • Ensure compliance with ASC 606/IFRS 15 revenue recognition standards across recurring and services revenue streams; develop an understanding of the billing and revenue cycle and work with Revenue Operations and Legal to align contract terms with revenue recognition.
  • Lead preparation of periodic financial statements for management, investors, and auditors.
  • Drive internal Budget versus Actual reporting for leadership and, with the CFO, update the company’s financial model, test assumptions, and support forecasts.
  • Manage finance systems, including NetSuite, Bill, Avalara, and related tools, ensuring accurate data flow, integration, and system utilization.
  • Develop, document, and implement internal controls, scalable processes, and continuous workflow and reconciliation improvements across finance functions.
  • Manage tax filings, sales and use tax, and regulatory compliance in partnership with external advisors.
  • Manage external audit, tax, and valuation providers and related audit and compliance activities.
  • Own cash management and risk management policies and their enforcement.
  • Supervise, mentor, and grow the accounting team, driving accountability and professional development.
Desired Qualifications
  • A master’s degree or CPA.
  • Experience designing and driving accounting and operational process change in high-growth, private-equity, or startup environments.

About the company

C

Claritas Rx

View
Website

Claritas Rx provides data integration and analytics for biopharma by unifying data from specialty pharmacies, commercial channels, clinical trials, patient support hubs, and copay cards into a cloud-based system. Its Ascend platform automates data integration and analysis to reveal the patient journey beyond trials, including real-world factors like fill rates and therapy duration. Patient Watchtower uses AI/ML to identify patients at risk of discontinuing treatment so care teams can intervene to support adherence, with daily updates and predictive analytics for prioritization. The company focuses on specialty and rare-disease therapies, especially oncology, to help biopharma firms improve patient adherence, optimize product launches and access, and strengthen commercial performance.

Company Size

51-200

Company Stage

N/A

Total Funding

N/A

Headquarters

South San Francisco, California

Founded

2011

Get referred to Claritas Rx

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • May 2026 leadership expansion added Keith Pensabene as CRO, signaling aggressive go-to-market scale.
  • 2026 launches and award wins validate product momentum, especially Patient Watchtower and Omnichannel CRM.
  • Early adopters reported 12%-40% higher consent fill rates and 11% stronger persistence.

What critics are saying

  • IQVIA and Veeva own adjacent pharma data workflows, squeezing Claritas Rx enterprise deals.
  • Client concentration in oncology and rare disease makes any lost anchor account painful fast.
  • If AI-driven consent or orchestration underperforms, biopharma teams replace Claritas Rx with internal stacks.

What makes Claritas Rx unique

  • Ascend unifies specialty-pharmacy, hub, copay, and field data into one longitudinal patient view.
  • Patient Watchtower and Omnichannel CRM connect risk detection with front-line action across therapy journeys.
  • Consent Clearinghouse centralizes consent across HIPAA, GDPR, CCPA, and state-law workflows.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Unlimited Paid Time Off
  • Stock Options
  • Remote Work Options
  • Flexible Work Hours
  • Hybrid Work Options

Growth & Insights and Company News

6 month growth

15%

1 year growth

15%

2 year growth

15%
Claritas Rx
Oct 13th, 2026
Claritas Rx appoints biopharma commercial leader Jonathan Witt to Board of Directors.

Claritas Rx appoints biopharma commercial leader Jonathan Witt to Board of Directors. Former Genentech Senior Vice President brings more than 25 years of biopharma experience to guide continued growth and patient impact. South San Francisco, CA, October 13, 2026 - Claritas Rx, the patient journey experts, today announced the appointment of Jonathan Witt to its Board of Directors. Mr. Witt is an accomplished senior executive with more than 25 years of experience in U.S. and global biopharmaceutical roles. He has a proven record of evaluating market opportunities across diverse therapeutic areas, setting development, commercialization, and corporate strategy, building and scaling enterprise capabilities, and transforming organizations to deliver leading customer experiences. Mr. Witt is the Chief Customer Experience Officer at Jazz Pharmaceuticals, where he leads the global commercial organization's evolution to deliver a seamless, differentiated patient and customer experience across all therapeutic areas. Before Jazz, Mr. Witt spent nearly 20 years at Genentech, most recently as Senior Vice President of Genentech Business Operations, a 1,000-person organization spanning omnichannel and customer experience, AI and advanced analytics, and patient access and support. He led the company's Integrated Customer Experience strategy, which delivered $700 million in portfolio revenue in 2024, and guided a multi-year transformation of Genentech's U.S. organization. He previously held vice president roles in pipeline strategy and commercialization, access and distribution, and market analysis and strategy. Earlier in his career, Mr. Witt spent four years at Pfizer in neuroscience new product development and three years in healthcare management consulting with Towers Perrin. He holds an MBA in marketing and strategic management from the University of Chicago Booth School of Business and a BA in economics from Princeton University. "After more than 25 years inside biopharma companies, I know firsthand how much depends on what happens between a prescription and a patient starting therapy," said Mr. Witt. "I've seen how hard it is for commercial and patient services teams to act on access barriers they can't see. Claritas Rx brings visibility to that part of the patient journey, along with the tools to resolve challenges before they disrupt care. I see tremendous potential for Claritas Rx solutions to power meaningful impact for biopharma customers and the patients they serve, and I'm excited to help guide the company's next stage of growth." "Jonathan has spent his career building the kind of customer-centric, data-driven commercial organizations our clients are working toward every day," said Michael Fitzgibbons, CEO of Claritas Rx. "His deep experience in patient access, omnichannel engagement, AI and analytics, and enterprise transformation will be invaluable as we continue to scale and deliver measurable results for rare disease and specialty brands and the patients they serve. We're delighted to welcome him to our Board." About Claritas Rx Based in South San Francisco, CA, Claritas Rx helps rare disease and specialty brands remove the barriers that keep patients from accessing and staying on the treatments they need. By uniting the most complete view of the patient journey with purpose-built technologies, Claritas Rx predict and resolve access challenges before they disrupt care. Its intelligent solutions combine advanced analytics, real-world data, AI, and in-line CRM capabilities to increase start and refill rates, reduce abandonment, and improve brand performance. For more information, visit www.ClaritasRx.com. Ready to transform patient access? See how Claritas Rx can help your organization remove barriers and improve patient outcomes

StreetInsider
Sep 2nd, 2026
Claritas Rx wins Fierce AI Innovation Award for Omnichannel Engagement Strategy.

Claritas Rx wins Fierce AI Innovation Award for Omnichannel Engagement Strategy. E-mail Address StreetInsider.com Top Tickers, 9/2/2026 September 2, 2026 11:37 AM EDT Patient Watchtower(TM) and Patient Services Omnichannel CRM Recognized for Turning Predictive Signals Into Coordinated Action Across the Patient Journey SOUTH SAN FRANCISCO, Calif.-(BUSINESS WIRE)- Claritas Rx, the patient journey experts, today announced it has won the Fierce AI Innovation Award in the Omnichannel Engagement Strategy category. The award recognizes Patient Watchtower(TM) and the Patient Services Omnichannel CRM - two connected AI-powered solutions that let biopharma manufacturers spot risk earlier in the patient journey and coordinate real-time action across every partner helping patients start and stay on therapy. Claritas Rx wins Fierce AI Innovation Award for Omnichannel Engagement Strategy. Patient Watchtower(TM) and Patient Services Omnichannel CRM recognized for turning predictive signals into coordinated action across the patient journey. For patients prescribed specialty and rare disease therapies, the path from prescription to treatment is fragile. Between 31% and 40% of specialty prescriptions go unfilled, and patients whose fill takes longer than 30 days convert at a rate 18 percentage points lower than those who fill sooner. Along the way, a single patient may touch a hub, a specialty pharmacy, a payer, and a copay program within days of each other, each generating data that, on its own, tells only part of the story. Historically, patient services teams have had to wait for a missed fill or a lapsed authorization to signal that a patient had already fallen off therapy. Patient Watchtower and the Patient Services Omnichannel CRM close that gap by connecting prediction to action at every stage of the journey. Patient Watchtower uses AI and machine learning to predict therapy discontinuation, prior authorization denial, and prescription abandonment up to 90 days in advance, with up to 80% precision. The moment a patient is flagged, the Patient Services Omnichannel CRM helps turns that signal into coordinated outreach, connecting case managers, hub partners, and specialty pharmacies in a single workflow so the right partner can respond before a patient drops off therapy. "Every stage of the patient journey generates a signal, but most teams don't see it until it's too late," said Michael Fitzgibbons, CEO of Claritas Rx. "This award reflects work that's built entirely around closing that gap - connecting the moment we detect risk to the moment someone acts on it, so patients start and stay on the therapies they need. That's the promise we make on every patient journey, and it's an honor to see our innovation recognized by Fierce and the industry." Since launching, Patient Watchtower and the Patient Services Omnichannel CRM have delivered measurable results across the patient journey, including a 20% improvement in fill rates, 17% increase in refill rates, a 98% partner response rate within 24 hours, and a significant reduction in manual case management burden - freeing patient services teams to focus on direct patient care rather than administrative reconciliation. The Fierce AI Innovation Awards, presented by Fierce Life Sciences, recognize organizations that are moving beyond AI pilots to deliver measurable impact across the biotech, pharma, and healthcare value chain, from R&D and clinical trials to commercialization, manufacturing, and care delivery. Entries were evaluated on innovation, impact, execution, scalability, and industry relevance. Winners were announced in Fierce Life Sciences' September 2 Special Report. About Claritas Rx Based in South San Francisco, CA, Claritas Rx helps rare disease and specialty brands remove the barriers that keep patients from accessing and staying on the treatments they need. Currently celebrating its 15-year anniversary, the company unites the most complete view of the patient journey with purpose-built technologies to predict and resolve access challenges before they disrupt care. Our intelligent solutions combine advanced analytics, real-world data, AI, and in-line CRM capabilities to increase start and refill rates, reduce abandonment, and improve brand performance. For more information, visit www.ClaritasRx.com.

Business Wire
Aug 11th, 2026
Claritas Rx named to the 2026 Inc. 5000 list for the second consecutive year.

Claritas Rx named to the 2026 Inc. 5000 list for the second consecutive year. Recognition Marks the Company's Second Straight Year on the Prestigious List of America's Fastest-Growing Private Companies - and Comes as Claritas Rx Celebrates 15 Years Partnering with Life Sciences Clients SOUTH SAN FRANCISCO, Calif.-(BUSINESS WIRE)-Claritas Rx, the patient journey experts, announced today it has been named to the 2026 Inc. 5000 list for the second consecutive year, earning a place among America's fastest-growing private companies. The list is the most prestigious ranking of the nation's most successful independent and entrepreneurial businesses, recognizing companies that have achieved remarkable growth while driving innovation, creating jobs, and shaping the future of the economy. Past honorees include companies such as Microsoft, Meta, Chobani, Oracle, and Patagonia. "This year is especially meaningful, as it also marks 15 years of Claritas Rx being a trusted partner to our clients. That commitment is what has fueled our growth year after year," said Michael Fitzgibbons, CEO of Claritas Rx. Share The back-to-back honor comes as Claritas Rx marks 15 years in business, a milestone that underscores the company's long-standing role as a trusted partner to biopharma companies working to help patients start and stay on therapy. "We are honored to be named to the Inc. 5000 for the second consecutive year," said Michael Fitzgibbons, CEO of Claritas Rx. "This year is especially meaningful, as it also marks 15 years of Claritas Rx being a trusted partner to our clients. That commitment is what has fueled our growth year after year. Making this list twice in a row is a reflection of the trust our clients place in us, and of a team that stays focused on our promise: progress for every patient journey." For the full Inc. 5000 list, honoree company profiles, and a searchable database by industry and location, please visit: www.Inc.com/Inc5000. "Every company on the Inc. 5000 has a story of perseverance, smart decision making, and a refusal to sit still," says Mike Hofman, editor-in-chief of Inc. "Their growth reflects more than strong financial performance-it reflects creativity, resilience, and the customer focus required to build companies that make a lasting impact. We congratulate all honorees on this significant achievement." About Inc. Inc. is the leading media brand and playbook for the entrepreneurs and business leaders shaping its future. Through its journalism, Inc. aims to inform, educate, and elevate the profile of its community: the risk-takers, the innovators, and the ultra-driven go-getters who are creating the future of business. Inc. is published by Mansueto Ventures LLC, along with fellow leading business publication Fast Company. For more information, visit www.Inc.com. About Claritas Rx Based in South San Francisco, CA, Claritas Rx helps rare disease and specialty brands remove the barriers that keep patients from accessing and staying on the treatments they need. Currently celebrating its 15-year anniversary, the company unites the most complete view of the patient journey with purpose-built technologies to predict and resolve access challenges before they disrupt care. Its intelligent solutions combine advanced analytics, real-world data, AI, and in-line CRM capabilities to increase start and refill rates, reduce abandonment, and improve brand performance. For more information, visit www.ClaritasRx.com. More News From Claritas Rx SOUTH SAN FRANCISCO, Calif.-( BUSINESS WIRE )-Claritas Rx, the patient journey experts, today announced Consent Clearinghouse(TM), a dedicated solution for standardizing and centralizing patient consent across oncology, rare disease, and specialty biopharma. As biopharma companies navigate an increasingly complex regulatory environment, including HIPAA, GDPR, CCPA, a growing patchwork of state privacy laws, and the emerging rules governing the use of AI, managing patient consent across multiple da... SOUTH SAN FRANCISCO, Calif.-( BUSINESS WIRE )-Claritas Rx, the patient journey experts, announced new leadership appointments designed to continue growth and scale. The company has welcomed Keith Pensabene as Chief Revenue Officer (CRO) and has promoted Meghna Misra to Vice President, Product and Shelly Howard to Vice President, Customer Operations. Mr. Pensabene brings more than 25 years of executive sales and revenue leadership experience across the life sciences and enterprise software secto... SOUTH SAN FRANCISCO, Calif.-( BUSINESS WIRE )-Claritas Rx, the patient journey experts, today announced that Bhupesh Bajaj, Chief Technology Officer, has been named to the prestigious PM360 ELITE 100 list in the Data Miners category. The annual recognition highlights the most exceptional, innovative, and transformative leaders shaping the healthcare and life sciences industries today. Mr. Bajaj was recognized for his groundbreaking work redefining how data is harnessed to drive meaningful outco... Claritas Rx. Release Versions

Business Wire
Jun 15th, 2026
Claritas Rx launches Consent Clearinghouse to centralise patient consent management in biopharma

Claritas Rx has launched Consent Clearinghouse, a platform designed to standardise and centralise patient consent management across oncology, rare disease and specialty biopharma. The solution provides a single, auditable source of consent data across multiple touchpoints including hubs, specialty pharmacies and copay programmes. The platform integrates consent data from across a brand's ecosystem into a unified dashboard, offering real-time visibility into consent status at patient, brand and channel levels. It supports compliance with HIPAA, GDPR, CCPA and state privacy laws, whilst enabling seamless integration with existing CRM and pharmacy platforms. South San Francisco-based Claritas Rx designed the solution to address growing regulatory complexity and the operational challenges of managing consent across multiple data sources and channel partners in specialty therapeutics.

Trade Show News
Jun 15th, 2026
Claritas Rx introduces Consent Clearinghouse(TM) to modernize Patient Consent Management across biopharma.

Claritas Rx introduces Consent Clearinghouse(TM) to modernize Patient Consent Management across biopharma. New Solution Gives Oncology and Rare Disease Teams a Centralized, Compliant View of Patient Consent Across the Full Therapy Journey New White Paper from Claritas Rx Entitled "Why Consent Management is Biopharma's Blind Spot" Now Available SOUTH SAN FRANCISCO, Calif.-(BUSINESS WIRE)-Claritas Rx, the patient journey experts, today announced Consent Clearinghouse(TM), a dedicated solution for standardizing and centralizing patient consent across oncology, rare disease, and specialty biopharma. "Real-time visibility into consent status isn't just about reducing compliance risk today; it's about building the trust infrastructure that will define how brands responsibly scale patient engagement tomorrow," said Mike Fitzgibbons, CEO of Claritas Rx. Share As biopharma companies navigate an increasingly complex regulatory environment, including HIPAA, GDPR, CCPA, a growing patchwork of state privacy laws, and the emerging rules governing the use of AI, managing patient consent across multiple data sources, specialty pharmacies, hubs, and channel partners has become a critical operational and compliance challenge. Consent Clearinghouse addresses this directly by providing a single, auditable source of truth for consent data across all touchpoints. Consent Clearinghouse integrates consent data from across a brand's ecosystem, including hubs, specialty pharmacies, field reimbursement managers, copay programs, and IOD/IDN channels, into a unified dashboard. Commercial and market access teams gain real-time visibility into consent status, enabling them to act on data with confidence while reducing compliance risk. "Commercial and market access teams can no longer afford to operate on fragmented consent data - the pace of AI-driven engagement has raised the stakes too high. Real-time visibility into consent status isn't just about reducing compliance risk today; it's about building the trust infrastructure that will define how brands responsibly scale patient engagement tomorrow," said Michael Fitzgibbons, CEO of Claritas Rx. "We built Consent Clearinghouse to give biopharma teams the visibility and control they need to operate compliantly, move faster, and ultimately serve more patients. This is particularly critical for patients in oncology and rare disease who can't afford delays caused by missing or mismanaged consent." Key Consent Clearinghouse capabilities include: * Unified consent tracking across all patient touchpoints and data sources * Real-time dashboard providing consent status visibility at the patient, brand, and channel level * Audit-ready reporting to support HIPAA, GDPR, CCPA, and state privacy compliance * Seamless integration with existing CRM, hub, and specialty pharmacy platforms * Role-based access controls to protect sensitive patient data across teams and partners With experience supporting numerous brands across oncology, rare, and specialty therapeutic areas, Claritas Rx designed Consent Clearinghouse specifically for the complex, high-stakes environment of specialty and rare disease therapies, where patient access barriers and compliance requirements are greatest. Consent and Compliance Thought Leadership Consent management is no longer just a compliance issue; it is a patient access issue. Claritas Rx's new white paper, "Why Consent Management is Biopharma's Blind Spot," breaks down where consent gaps form, what they cost, and how leading biopharma teams are building a more unified, audit-ready approach across the full therapy journey. A companion webinar, "The Hidden Risk in Your Access Strategy: Rethinking Patient Consent Management," will take place on August 19 at 10 am PT (1 pm ET). Media may request a copy of the white paper or registration to the webinar by contacting Emily Brennan. About Claritas Rx Based in South San Francisco, CA, Claritas Rx helps rare disease and specialty brands remove the barriers that keep patients from accessing and staying on the treatments they need. By uniting the most complete view of the patient journey with purpose-built technologies, Business Wire, Inc. predict and resolve access challenges before they disrupt care. Its intelligent solutions combine advanced analytics, real-world data, AI, and in-line CRM capabilities to increase start and refill rates, reduce abandonment, and improve brand performance. For more information, visit www.ClaritasRx.com. More News From Claritas Rx SOUTH SAN FRANCISCO, Calif.-( BUSINESS WIRE )-Claritas Rx, the patient journey experts, announced new leadership appointments designed to continue growth and scale. The company has welcomed Keith Pensabene as Chief Revenue Officer (CRO) and has promoted Meghna Misra to Vice President, Product and Shelly Howard to Vice President, Customer Operations. Mr. Pensabene brings more than 25 years of executive sales and revenue leadership experience across the life sciences and enterprise software secto... SOUTH SAN FRANCISCO, Calif.-( BUSINESS WIRE )-Claritas Rx, the patient journey experts, today announced that Bhupesh Bajaj, Chief Technology Officer, has been named to the prestigious PM360 ELITE 100 list in the Data Miners category. The annual recognition highlights the most exceptional, innovative, and transformative leaders shaping the healthcare and life sciences industries today. Mr. Bajaj was recognized for his groundbreaking work redefining how data is harnessed to drive meaningful outco... SOUTH SAN FRANCISCO, Calif.-( BUSINESS WIRE )-Claritas Rx, the patient journey experts, today announced the availability of its Patient Services Omnichannel CRM. The new solution enables clients to engage rapidly and consistently across the full patient-care ecosystem - from specialty and independent pharmacies to hubs, field teams, case managers, and other key stakeholders - accelerating patient support and streamlining communication for a faster, better experience at every stage of care. By unify... Claritas Rx. Release Versions